Kamada Shares Up 1% On Light Volume; Co. Earlier Offered Interim Results From Phase 2 Trial Of IV Alpha-1 Antitrypsin Treatment, Showed 'Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment'